Ask AI
EGFRm NSCLC Progression on Osimertinib

CE / CME

Management of a Patient With EGFR-Mutated NSCLC and Progression on First-line Osimertinib

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: April 17, 2026

Expiration: October 16, 2026

Activity

Progress
1 2
Course Completed

Case Follow-up
Your patient receives 4 cycles of carboplatin plus pemetrexed while continuing osimertinib, followed by maintenance pemetrexed with ongoing osimertinib because of continued CNS control. She initially achieves disease stabilization, but 6 months later, restaging CT shows renewed systemic progression. Brain MRI remains stable, Eastern Cooperative Oncology Group performance status is 1, and organ function remains adequate.

Which of the following treatment options would you recommend as the next step in her care now?